Mitsubishi UFJ Asset Management Co. Ltd. Buys 9,002 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Mitsubishi UFJ Asset Management Co. Ltd. increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 120,787 shares of the biopharmaceutical company’s stock after buying an additional 9,002 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.09% of Alnylam Pharmaceuticals worth $55,079,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Root Financial Partners LLC bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC bought a new stake in Alnylam Pharmaceuticals in the third quarter worth $27,000. Atlantic Union Bankshares Corp purchased a new stake in Alnylam Pharmaceuticals during the second quarter valued at $30,000. ORG Partners LLC lifted its position in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 33 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at $37,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 0.5%

Shares of ALNY opened at $332.92 on Friday. The firm has a fifty day moving average price of $360.54 and a 200-day moving average price of $418.88. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $44.15 billion, a P/E ratio of 194.69 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company’s quarterly revenue was up 84.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.65) EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Leerink Partners decreased their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research report on Monday, December 15th. Raymond James Financial reaffirmed an “outperform” rating and issued a $472.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, January 12th. Royal Bank Of Canada dropped their target price on Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a report on Tuesday, January 20th. Finally, Needham & Company LLC decreased their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Insider Activity

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,959 shares of the company’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the completion of the sale, the executive vice president directly owned 31,769 shares in the company, valued at approximately $9,850,931.52. This represents a 5.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Pushkal Garg sold 2,242 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the transaction, the executive vice president owned 24,848 shares in the company, valued at approximately $7,704,867.84. This represents a 8.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 36,578 shares of company stock valued at $12,416,105. Insiders own 1.50% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.